Jackson Nagamoto

发表

Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2–associated schwannomas reveals differences in efficacy and drug resistance development

Julia N. Soulakova, Juan I. Young, F. Telischi, 2019, Neuro-oncology.